Comparative Pharmacology
Head-to-head clinical analysis: ALTABAX versus THERMAZENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTABAX versus THERMAZENE.
ALTABAX vs THERMAZENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retapamulin is a pleuromutilin antibiotic that selectively inhibits bacterial protein synthesis by interacting with the 50S ribosomal subunit, specifically at the L3 ribosomal protein and the peptidyl transferase center, thereby preventing peptide bond formation.
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and causing cell death. It also has anti-inflammatory effects by modulating cytokine release.
1% ointment applied topically to affected area twice daily for 5 days. Total treatment area should not exceed 100 cm². Maximum single dose is 0.5 g per 100 cm².
1% cream applied topically once or twice daily; for burns, apply 1/16-inch thick layer over entire burn area.
None Documented
None Documented
Terminal half-life is approximately 11-14 hours in adults after topical application, supporting twice-daily dosing.
Terminal elimination half-life is approximately 22 hours (range 17–28 h) in patients with normal renal function, enabling twice-daily dosing in most cases.
Retapamulin is primarily eliminated via the fecal route (96.5% of dose), with minimal renal excretion (<0.5% of dose).
Renal: ~65% unchanged; biliary/fecal: ~35% as metabolites and unchanged drug.
Category C
Category C
Topical Antibiotic
Topical Antibiotic